signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca...

28
Signatures muta-onnelles et évolu-on clonale des tumeurs Rencontres scien-fiques des Grands Causses Eric Letouzé Equipe "Génomique Fonc-onnelle des Tumeurs Solides", INSERM U1162 29 septembre 2015

Upload: others

Post on 10-Jan-2020

4 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

Signatures  muta-onnelles  et  évolu-on  clonale  des  tumeurs    

Rencontres  scien-fiques  des  Grands  Causses  

Eric  Letouzé  Equipe  "Génomique  Fonc-onnelle  des  Tumeurs  

Solides",  INSERM  U1162  

29  septembre  2015  

Page 2: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

PLAN  

1.  Signatures  muta-onnelles  

2.  Evolu-on  clonale  des  tumeurs  2.1)  Introduc-on  à  l’évolu-on  clonale  des  tumeurs  2.2)  Approche  1  :  plusieurs  tumeurs  d’un  même  pa-ent  2.3)  Approche  2  :  plusieurs  prélèvements  d’une  même  tumeur  2.4)  Approche  3  :  au  sein  d’un  même  échan-llon  tumoral  

1.1)  Principe  des  analyses  de  signatures  muta-onnelles  1.2)  Applica-on  aux  cancers  du  foie  

Page 3: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

1.  Signatures  muta-onnelles  

2.  Evolu-on  clonale  des  tumeurs  2.1)  Introduc-on  à  l’évolu-on  clonale  des  tumeurs  2.2)  Approche  1  :  plusieurs  tumeurs  d’un  même  pa-ent  2.3)  Approche  2  :  plusieurs  prélèvements  d’une  même  tumeur  2.4)  Approche  3  :  au  sein  d’un  même  échan-llon  tumoral  

1.1)  Principe  des  analyses  de  signatures  muta-onnelles  1.2)  Applica-on  aux  cancers  du  foie  

PLAN  

Page 4: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

Les  spectres  muta-onnels  diffèrent  en  fonc-on  du  type  tumoral  (version  2002)  

Pfeifer  et  al.  2002  

A  G  C  

T  C  G  

A  G  C  

T  A  G  

A  T  C  

T  A  G  

DNA  mispairing  

DNA  replica-on  

Benzo[a]pyrene  Benzo[a]pyrene  adduct  on  guanine  

G>T  (or  C>A)  muta-on  

TP53  muta-ons  

Page 5: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

!  Different  cancers  have  different  muta-on  rates:  

Alexandrov  et  al.,  Nature  2013  

Lawrence  et  al.,  Nature  2013  

!  Different  cancers  display  different  types  of  muta-ons:  

Les  spectres  muta-onnels  diffèrent  en  fonc-on  du  type  tumoral  (version  2015)  

Page 6: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

Le  spectre  muta-onnel  d’une  tumeur  reflète  l’accumula-on  de  plusieurs  processus  mutagènes  

Helleday  et  al.,  Nat  Rev  Genet  2014  

Page 7: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

MÉTHODE  :  Extraire  les  signatures  muta-onnelles  à  par-r  de  données  de  séquençage  à  haut  débit  

!  The  muta-onal  landscape  of  a  tumor  results  from  the  combina-on  of  several  muta/onal  processes  opera-ve  with  different  intensi/es.  

Alexandrov  et  al.,  Cell  Rep  2013  

Page 8: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

!  The  problem  is  to  find  the  muta/onal  processes  (P)  and  the  exposures  (E)  while  only  knowing  the  muta/onal  pa:ern  of  each  sample  (M).    

M  

P  

E  

R  

!  This   is   similar   to   the  cocktail  party  problem,  and  can  be  solved  with   the  non-­‐nega-ve  matrix  factoriza-on  (NMF)  algorithm.  

M  =  P  x  E  +  R   Alexandrov  et  al.,  Cell  Rep  2013  

Page 9: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

!  Applica-on  of   this  method   to   >7,000   cancers   iden-fies  21   signatures,   associated  with   known  or  new  oncogenic  mechanisms.  

Signature  10  :  DNA  polymerase  E  deficiency  

Signature  4:  Tobacco  

Signature  16  :  New  mutagenic  mechanism?  

Alexandrov  et  al.,  Nature  2013  

Page 10: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

!  Associa-on  of  signatures  with  tumor  type  and  e-ology:  

-­‐>  Most  signatures  remain  to  be  explained!  

Page 11: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

1.  Signatures  muta-onnelles  

2.  Evolu-on  clonale  des  tumeurs  2.1)  Introduc-on  à  l’évolu-on  clonale  des  tumeurs  2.2)  Approche  1  :  plusieurs  tumeurs  d’un  même  pa-ent  2.3)  Approche  2  :  plusieurs  prélèvements  d’une  même  tumeur  2.4)  Approche  3  :  au  sein  d’un  même  échan-llon  tumoral  

1.1)  Principe  des  analyses  de  signatures  muta-onnelles  1.2)  Applica-on  aux  cancers  du  foie  

PLAN  

Page 12: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

Le  spectre  muta-onnel  des  carcinomes  hépatocellulaires  

!  Average  muta-onal  spectrum  over  243  HCC  analyzed  by  WES:  

Spontaneous  deamina-on  of  methylated  CpGs  

T>C  muta-ons  in  an  AT[AGT]  context,  characteris-c  of  liver  

tumors  

C>A  muta-ons  enriched  in  a  subset  of  HCC  

Page 13: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

ACA

ACC

ACG

ACT

CCA

CCC

CCG

CCT

GCA

GCC

GCG

GCT

TCA

TCC

TCG

TCT

ACA

ACC

ACG

ACT

CCA

CCC

CCG

CCT

GCA

GCC

GCG

GCT

TCA

TCC

TCG

TCT

ACA

ACC

ACG

ACT

CCA

CCC

CCG

CCT

GCA

GCC

GCG

GCT

TCA

TCC

TCG

TCT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

0.0

0.1

0.2C>A C>G C>T T>A T>C T>G

Signature  1A  

•  Ubiquitous  in  human  cancers  •  Reflects  the  spontaneous  deamina-on  of  methylated  Cs  at  CpG  sites  •  Associated  with  age  

Signature  4  

•  Mostly  found  in  lung  and  liver  cancers  •  Not  associated  with  smoking  in  our  series.  

ACA

ACC

ACG

ACT

CCA

CCC

CCG

CCT

GCA

GCC

GCG

GCT

TCA

TCC

TCG

TCT

ACA

ACC

ACG

ACT

CCA

CCC

CCG

CCT

GCA

GCC

GCG

GCT

TCA

TCC

TCG

TCT

ACA

ACC

ACG

ACT

CCA

CCC

CCG

CCT

GCA

GCC

GCG

GCT

TCA

TCC

TCG

TCT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

0.00

0.05

0.10C>A C>G C>T T>A T>C T>G

!  Using  the  Wellcome  Trust  Sanger  Ins-tute  method,  we  iden-fied  8  dis/nct  signatures  in  our  HCC  series:  

Page 14: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

Signature  16  

•  T>C  muta-ons  at  AT[AGT]  trinucleo-des  •  Liver-­‐specific  signature  

ACA

ACC

ACG

ACT

CCA

CCC

CCG

CCT

GCA

GCC

GCG

GCT

TCA

TCC

TCG

TCT

ACA

ACC

ACG

ACT

CCA

CCC

CCG

CCT

GCA

GCC

GCG

GCT

TCA

TCC

TCG

TCT

ACA

ACC

ACG

ACT

CCA

CCC

CCG

CCT

GCA

GCC

GCG

GCT

TCA

TCC

TCG

TCT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

0.00

0.05

0.10C>A C>G C>T T>A T>C T>G

G G T   A T T

C C A T A A

5'   3'  

3'   5'  

transcribed  strand  

non-­‐transcribed  strand  G G T   A T T

C C A T A A

5'   3'  

3'   5'  

Transcrip-on  coupled  repair  (TCR)   G G T   A T T

C C A T A A

5'   3'  

3'   5'  

T>C  muta-on  on  the  transcribed  strand  

Less  efficient  TCR  

G G T   A C T

C C A T A A

5'   3'  

3'   5'  

•  Very  strong  transcrip-onal  strand  bias:  

G G T   A T T

C C A T A A

5'   3'  

3'   5'  

Bulky  DNA  adduct  

Page 15: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

Signature  23  

•  Found  in  a  single  tumor  with  >  6000  muta-ons  •  Non-­‐cirrho-c  liver  but  with  black  mineral  deposits  

ACA

ACC

ACG

ACT

CCA

CCC

CCG

CCT

GCA

GCC

GCG

GCT

TCA

TCC

TCG

TCT

ACA

ACC

ACG

ACT

CCA

CCC

CCG

CCT

GCA

GCC

GCG

GCT

TCA

TCC

TCG

TCT

ACA

ACC

ACG

ACT

CCA

CCC

CCG

CCT

GCA

GCC

GCG

GCT

TCA

TCC

TCG

TCT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

0.0

0.1

0.2C>A C>G C>T T>A T>C T>G

Throrotrast?  

Schulze,  Imbeaud,  Letouzé  et  al.,  Nat  Genet  2015  

Signature  24  

ACA

ACC

ACG

ACT

CCA

CCC

CCG

CCT

GCA

GCC

GCG

GCT

TCA

TCC

TCG

TCT

ACA

ACC

ACG

ACT

CCA

CCC

CCG

CCT

GCA

GCC

GCG

GCT

TCA

TCC

TCG

TCT

ACA

ACC

ACG

ACT

CCA

CCC

CCG

CCT

GCA

GCC

GCG

GCT

TCA

TCC

TCG

TCT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

0.0

0.1

0.2C>A C>G C>T T>A T>C T>G

•  5  pa-ents,  all  from  African  countries  •  3/5  pa-ents  present  the  R249S  muta-on  of  TP53  

Aflatoxin  B1  

Deux  nouvelles  signatures  iden-fiées  dans  les  CHC  

Page 16: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

U-lité  clinique  des  signatures  muta-onnelles  

!  Example  1  :  Iden-fy  a  mutagenic  exposure  

!  Example  2  :  Iden-fy  a  predisposing  muta-on  

Signature  of  a  known  DNA  repair  defect  

Perc

enta

ge o

f mut

atio

ns

ACA

ACC

ACG

ACT

CC

AC

CC

CC

GC

CT

GC

AG

CC

GC

GG

CT

TCA

TCC

TCG

TCT

ACA

ACC

ACG

ACT

CC

AC

CC

CC

GC

CT

GC

AG

CC

GC

GG

CT

TCA

TCC

TCG

TCT

ACA

ACC

ACG

ACT

CC

AC

CC

CC

GC

CT

GC

AG

CC

GC

GG

CT

TCA

TCC

TCG

TCT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

ATA

ATC

ATG

ATT

CTA

CTC

CTG CTT GTA

GTC

GTG GTT TTA

TTC

TTG

TTT

0.000

0.105

0.210

C>A C>G C>T T>A T>C T>G

Adrenocor-cal  carcinoma  ACC39  

Aflatoxine  B1  

Page 17: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

1.  Signatures  muta-onnelles  

2.  Evolu-on  clonale  des  tumeurs  2.1)  Introduc-on  à  l’évolu-on  clonale  des  tumeurs  2.2)  Approche  1  :  plusieurs  tumeurs  d’un  même  pa-ent  2.3)  Approche  2  :  plusieurs  prélèvements  d’une  même  tumeur  2.4)  Approche  3  :  au  sein  d’un  même  échan-llon  tumoral  

1.1)  Principe  des  analyses  de  signatures  muta-onnelles  1.2)  Applica-on  aux  cancers  du  foie  

PLAN  

Page 18: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

Le  modèle  d’expansion  clonale  

Nik-­‐Zainal  et  al.,  Cell  2012  

Page 19: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

U-liser  l'évolu-on  clonale  pour  reconstruire  l'ordre  d'appari-on  des  altéra-ons  géné-ques  

!  Comparing   the   profiles   of   different   clones   can   help   reconstruc-ng   the   order   in   which  genomic  altera-ons  occured:  

Normal'cell'Common'precursor'1'

Common'precursor'2'

Clone'1'

Clone'2'

Clone'3'

≠  tumors  

≠  parts  of  a  same  tumor  

≠  cell  popula-ons  within  a  same  sample  

Page 20: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

Approche  1  :  plusieurs  tumeurs  d’un  même  pa-ent  

Primary  tumor  

Recurrence  

Chromosome  aberra-ons  

Letouzé  et  al.,  Genome  Biol  2010  

!  Common  breakpoints  in  recurrent  bladder  cancers  can  be  used  to  reconstruct  the  -ming  of  CNAs  in  cancer  progression:  

Page 21: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

Analyse  de  couples  adénome  -­‐>  carcinome  hépatocellulaire  par  séquençage  exome  

!  Comparing  the  muta-ons  in  HCA  and  HCC  from  the  same  pa-ents  reveals  the  importance  of  TERT  muta-ons  for  the  transforma-on  of  CTNNB1-­‐mutated  adenomas:  

Adenomas   Carcinomas  

Adenoma   Carcinoma  

!  Common  sequence  in  HCA  -­‐>  HCC  progression:  

Normal  liver  

CTNNB1  muta-on  

TERT  muta-on  

Pila-  et  al.,  Cancer  Cell  2014  

Page 22: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

Approche  2  :  plusieurs  prélèvements  d’une  même  tumeur  

!  Mul--­‐region   sequencing   reveals   intra-­‐tumor  heterogeneity  in  8/12  breast  cancers:  

-­‐>  Tumor  heterogeneity  should  be  considered  when  designing  targeted  therapy  trials.  

Yates  et  al.,  Nat  Medicine  2015  

Page 23: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

Approche  3  :  au  sein  d’un  même  échan-llon  tumoral  

!  Low-­‐amplitude   copy-­‐number   changes   and  muta-ons   with   a   low   allelic   frac-on   reveal  subclonal  altera-ons:  

Nik-­‐Zainal  et  al.,  Cell  2012  

Variant allele fraction

VAF  =  Number  of  mutated  reads/Total  number  of  reads  

Page 24: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

Analyse  sous-­‐clonale  mul--­‐échan-llons  :    Transforma-on  adénome  -­‐>  carcinome  hépatocellulaire  

●●

●●

●●

● ●

● ●

●●

●●

●●

●●

● ●

●●

●●

● ●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

● ●

● ●

●●●

●●

●●

● ●

●●

●●

●●

●●

●●

●●

●●

● ●

●●

●● ●

●●

●●

●●

●●

● ●

●●

●●

●●

●●

●● ●

●●

● ●

●●

●●

●●

●●

●●

● ●

●●

● ●

●●

●●

●●

●●●

● ●

● ●

●● ●●

●●●●

● ●

● ●

●●

●●

●●

●●

●●

●●

●●

● ●●

●●

● ●

●●

●●

●●

●●

●●

● ●

●●

●●

● ●

●●

●● ●

●●

● ●

● ●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●●

●●

●●

● ●

●● ●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

● ●

●●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

● ●

● ●●

●●

●●●

●●

●●

● ●

● ●

●●● ●

●●

● ●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

● ●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

● ●●

0.0 0.2 0.4 0.6 0.8

0.0

0.2

0.4

0.6

0.8

CHC464T

CHC465T

●● ● ●●● ●● ●● ● ●●● ●●●●●● ● ●● ●●● ●●●● ●●●● ●● ● ●●●● ● ●●●●● ●● ●●●● ●●●● ●● ●● ●● ●● ●● ●● ●●● ●● ●●●●●● ●● ●● ●● ●●● ●●● ● ●●●● ● ●● ● ●●●● ●●●●● ● ●●● ●● ● ● ●●● ●●● ●●● ●●● ●●●●● ● ●●●● ●● ●●● ● ●● ●● ● ●● ●●● ●●● ●●● ● ● ●●● ●● ● ● ● ●● ●●●●● ● ●● ●●● ● ●●●●● ●● ●● ●●● ●●● ●●● ●●●● ●●●● ●● ●●● ● ●●● ● ● ●●● ●●●●● ●●●● ● ● ●● ●● ●● ●●● ● ● ●● ● ●●● ●● ● ●● ●● ● ●● ●●●● ● ●●● ●● ●● ●●●● ●● ●● ●● ● ●●● ●● ● ●● ●●● ●● ●● ●●● ●●● ● ●●● ●●●● ● ●●●● ●● ●● ●● ●● ●● ●●● ● ●●●●●● ● ●● ●●● ● ●●● ●●●●● ●●● ● ● ●● ● ●●● ●● ●●●●●● ●● ●●● ●●● ●●● ● ●● ●●● ●●● ●●● ●●● ●●●● ●● ● ● ● ●● ●●● ●● ● ●●● ●●● ●●●● ●●● ●● ●● ●● ●●●●●● ● ● ●● ●● ●● ●●● ●● ●● ● ●● ● ●●●● ●●● ● ●●●● ●●●● ●● ● ●● ● ●●● ●● ● ●●● ● ●●●●● ● ●●● ●● ● ●●● ● ●● ●● ●●●● ●● ●●●●●● ● ●● ● ●● ●● ●●●●● ● ●● ●● ●●● ●● ●● ●●● ●●●●● ●● ● ●●●● ●● ●● ●● ● ●●● ●● ●● ●● ●● ●●●● ● ●●●●●● ●● ●●●● ● ●● ●● ● ●●●● ● ● ●●● ●●● ●●● ●●● ●● ●● ●● ●●●●● ● ●●● ● ●●●● ● ●● ● ●●●●●● ●● ●●●●●● ●● ●●● ●● ●● ●●● ● ●● ●● ●●●●●● ● ●● ●●●● ●● ● ●●●● ● ● ●● ● ●● ●●● ● ●●●● ● ●●●●●● ●● ●● ●● ●●●● ●● ●● ●●● ●●●● ●● ●●●● ●●●●● ●●●●●● ●●● ●●●● ● ● ● ●● ●● ●●● ● ● ●●● ●●● ●● ●● ●●● ●●● ●● ●● ● ●●● ● ●●●● ● ●●● ● ●● ●● ●●●● ● ●●●● ●●● ●● ●● ● ● ●● ●● ●● ● ●● ●●● ● ●●●●● ● ●● ●● ●● ●●●● ●●● ●●● ● ● ●● ● ●●● ●●●●● ●●●● ● ●●● ●●●● ●● ●● ●●● ●●● ● ●● ●●● ●● ● ●●● ●● ●●● ●●● ● ●●● ●● ● ●●● ●● ●● ● ●●● ● ●● ●●● ● ●●●●● ●● ●●●● ●● ● ●● ●●● ● ● ● ●●● ●●● ●● ●● ● ● ●● ●●●● ● ●● ● ●●●●● ●● ● ●● ● ●● ●●●● ●● ●●● ●● ●●● ● ● ●● ● ●● ●●● ●● ●● ● ●● ● ●●● ●●● ●●●● ●● ●● ●● ●●● ● ●●● ●●●●● ● ●●●● ●●● ●● ● ●● ●●● ●●● ● ●●● ●● ●●●●●● ● ● ●●●●● ●● ● ●● ● ●● ●● ●●● ● ● ●● ●●● ●● ●●● ●●●● ●●● ●● ●●● ●● ●● ●● ● ● ●●● ●●● ●●●● ●●● ● ●● ●●●● ●●● ●●● ● ●●●● ●● ●● ● ●●●● ●● ●● ● ● ●●● ●●● ●●●● ● ● ●●●● ●●●● ●●●● ●● ●●● ●●● ●● ●● ●● ●●● ●● ●●●● ● ●● ●● ●●●●● ●●● ● ●●● ● ●● ●●● ●●● ●● ● ●● ● ●● ●● ● ●● ●● ●●● ●●● ●● ● ● ●●● ●● ●●● ● ●● ●●● ●● ● ● ●● ●● ●● ●● ● ● ●● ●●● ●● ●●● ●●●●●● ● ● ●● ●●●●● ●● ●● ● ●●● ●● ●●● ●● ● ●●● ●●●● ●●● ● ●●● ●● ●● ● ● ●●● ●● ●● ● ●● ●●● ● ●● ●● ●● ●● ● ●● ● ● ●● ●● ●● ●● ●● ●● ● ●●●● ●● ●● ● ● ●● ●●● ● ●●● ●●● ●●●●● ●● ●●●● ●●● ● ● ●●● ●●● ●● ● ●●● ● ●●● ●● ●● ●● ● ●●●● ● ●● ● ● ● ●● ●●● ● ●●●●●● ●●●● ● ●● ● ● ●●● ●●●●● ● ●● ●●● ●●● ●● ●● ●●●●● ●● ● ●●●● ● ●●●● ●● ● ●● ● ●● ●● ●●● ●● ●● ●● ●● ● ● ● ●● ●● ●●●● ●● ●● ●● ● ● ●●●● ●● ●● ● ● ● ●●● ●● ●● ●●●● ● ●● ● ●●● ●●●● ● ● ● ● ●● ●● ● ●●● ●●●●●● ● ● ●●●● ●●● ●● ●● ●●● ●●● ●●●●● ●●● ● ●● ●● ● ●●● ●● ●● ●● ●● ●● ●● ●● ●●●● ●● ●● ●● ●● ●●●● ●●●● ●● ●●●●●● ● ● ● ●● ●●●● ●●● ●●●●● ●● ● ● ● ● ●● ●● ●● ●● ●● ●●● ●● ●● ● ●● ●● ● ●● ● ●●● ● ●●● ●●● ●● ● ●● ● ●● ●● ●● ● ● ●●● ● ●●●● ●●●● ●● ● ● ●● ●● ●● ●● ●●● ●●● ●● ●● ●●●● ●●● ●● ●●● ●●● ● ●● ●●●●● ●●●● ● ●●●●●● ● ●● ●●●● ●● ●●● ●●● ●● ● ●●● ● ●● ●●●● ●●● ● ●●● ●●●● ●● ●● ●● ●● ●● ●● ● ●● ●● ●● ●● ● ●● ●● ● ●● ● ●● ● ●● ●● ●●● ●●● ●● ●● ●● ●●● ●●● ●●● ●● ●●● ● ●●● ●● ●●●● ● ●● ●● ● ●●● ●● ● ●●● ● ● ●● ●● ●● ● ●● ●● ●● ● ●● ●● ● ●●●●● ● ● ●●● ●● ●● ●● ●●● ● ●● ●●●●● ●● ●● ●● ●●● ●●● ●●● ● ●●● ●●●● ● ● ● ● ●●● ● ● ●● ● ●● ●● ●●●● ●●●●● ●●● ●● ●● ●●● ●● ●● ●●●●● ●●● ●● ●● ●● ●●●● ●●● ● ●●● ● ●●●● ●● ●●● ● ●● ● ● ● ●●●● ●● ●●● ● ●● ●● ● ●● ● ● ●●● ●●● ●●● ●●● ●●●●● ●●● ● ●●● ●● ● ●●●● ●●● ● ●●● ●● ●● ●● ● ●●●● ● ●● ●●● ●●● ● ●●● ●● ●● ● ● ●●● ●●●● ●● ●●● ● ●● ●● ●● ●● ●● ● ●● ● ●● ● ● ●● ●● ● ●● ● ● ●●●● ●●● ●●● ● ●●● ● ● ●● ● ●● ●●●● ●● ●●● ●● ●●● ●● ● ●● ●●● ● ●●● ●●● ● ●●●● ●●● ● ●● ●●● ●●● ●●●●●● ● ●●● ● ●●●● ●● ●● ●● ●● ● ●● ●● ●● ● ●●● ●●● ●●● ● ● ●● ●●● ●● ●● ● ●●●● ●● ● ●●●● ● ●● ●● ● ●●● ●● ●● ● ●●● ● ●● ●● ● ●●● ● ● ●● ● ●●● ●●●● ● ●● ●● ●● ● ●●●● ●●● ● ●● ●●● ●●● ● ●●●●● ● ● ●● ●● ●●● ● ●●● ●●●●● ● ● ● ●●● ●● ●● ● ●● ●● ● ●●●● ●●●● ●● ● ●●● ● ● ●●● ● ●● ●●●●● ● ●● ●● ●● ●●●● ● ● ●●● ●●● ●● ●● ●● ●● ●●●●●● ●● ●● ●●● ●●● ● ●●● ● ●● ● ● ●● ●● ●● ●● ●●● ● ●●●● ●●●● ●● ● ●●●● ●●● ●● ● ●●●● ● ● ●●●●● ●● ●●● ●●● ●●● ● ● ●●● ●●●●●●● ●●● ●● ● ●● ● ●●●● ● ●●● ●●● ● ●● ●● ●● ● ●● ● ● ●● ●●●●● ● ●● ●● ● ●● ●● ●●●●● ● ●● ●● ●● ●●● ●● ●● ● ●● ●●● ● ●● ●●●● ●●●● ●●● ● ● ●●● ●● ● ●●● ●●● ●● ●● ● ●● ●● ●● ●●● ● ●● ●●● ●● ●● ●● ●●● ●●● ●●● ●●● ● ●●● ●● ● ● ●●● ●●●●●● ● ●●● ●● ●● ●● ●● ● ●●● ●● ● ●●● ● ●● ●●●●● ●●● ● ●● ●●● ●●● ● ●● ● ● ●● ● ●●●● ●● ●●● ●●● ●●●● ●●●●● ● ● ●● ● ●● ● ●● ●●● ● ●● ● ●● ● ●● ● ●●● ●● ● ●● ●● ● ●●● ●●●●● ●●●●● ● ●●●● ●● ●●● ● ●●●●● ● ●●● ●● ● ● ●●●● ●● ●●● ●●● ● ●● ●● ●● ●●● ●●● ●●●●● ●● ●●●● ● ●●●●●● ●● ●●● ●●● ●●●● ●● ●●● ●●● ●● ●●● ●● ● ●●● ●● ●●●● ●● ●● ● ●● ●●● ● ●●●● ● ●● ●● ●● ●●● ●● ●● ●● ●●●● ●● ●●● ●● ● ●● ●● ● ●●● ●●●● ●●● ●● ●● ● ●● ●● ● ●● ●●● ●● ●● ● ●●●● ●●●● ●●●● ● ●● ● ●● ●●● ●●●●● ● ●● ●● ●● ●●● ●●● ●● ● ●●● ●● ●● ● ● ●● ●●● ●● ●●● ●● ● ●● ● ●● ●●● ●● ●● ● ●●● ●●● ●●● ● ● ●● ●● ●● ●●●● ●● ● ●●● ●●● ●●●●● ●● ●●● ● ● ● ●●● ●●●● ●● ●● ●● ●●●● ●●●●● ●● ●● ●●●●● ● ●●● ●●● ● ●● ●● ●●● ● ●●● ●●●● ● ●● ●●●●● ●●●● ●●● ● ● ●●●●●● ● ● ●● ●●●● ●● ● ●●● ●● ●● ● ● ●● ● ●● ●●● ●●●● ● ●●● ●● ●●● ● ● ●●●● ●● ●●●●● ●●● ●● ●●● ● ● ●● ●● ●● ●●●● ●● ●● ● ●● ●● ●● ●● ●●●●● ●● ●● ●●● ●●● ● ● ●● ●●● ●●● ●● ●●● ● ●● ●●●● ● ●●● ●● ●●● ●●●● ● ●●● ●● ●●●● ● ●●●● ●● ● ● ●●●● ● ●● ●● ●● ●●●● ●● ● ●● ●●● ● ●● ●●● ●●● ●●●●● ● ●●●●● ●●●● ●● ●● ●●●● ●● ●● ●● ●● ●● ●●●● ●● ●●● ●● ●●●●● ●●● ●●● ●●● ●●● ● ●●● ●●● ●●● ● ●● ●● ●● ●●●●● ●● ●●●● ●● ● ●●●●●● ●● ● ●● ●● ●●● ●● ● ● ●● ● ●● ● ●●●● ●●● ● ●● ●● ●●● ●● ● ●● ●● ●●● ●●● ● ●● ●●●●●●●● ● ●● ●● ●● ●●●● ●●● ● ●● ●● ●● ●● ●●● ● ●● ●● ●●● ● ●● ● ●●● ● ●● ● ●●● ● ●●● ●● ●●● ● ● ●●● ●● ●● ● ● ●● ● ●● ●●● ● ●●●● ●●● ●●● ● ●● ● ●● ●●● ● ●● ● ●● ●●●●● ●● ● ●● ● ● ● ●●● ● ●●● ● ●●●●● ●●● ●● ●●● ●● ●● ●● ●● ● ●●● ● ● ●● ●● ● ●● ●● ● ●● ●● ●●●● ●●● ●●● ● ● ●● ●●●● ●●● ●● ●●●●●● ●●● ●●●● ●● ●●● ●● ●●● ● ●●●● ● ●● ●●● ●● ●● ●●●●● ●●● ● ●● ●● ●●● ● ●● ●●● ● ● ●● ● ●●●●● ●● ●●● ●●●●● ●● ●● ● ●●● ●●● ●● ●● ●● ●● ●●●●● ●●●● ● ●● ● ●●●● ● ●● ● ●●● ●●● ● ●●● ● ●● ●● ● ●●● ●● ●● ● ●●●● ● ●●● ● ●● ●●● ●● ●● ● ● ●●●● ● ●●●●● ● ●● ●●● ●●● ●● ●● ●●●●●● ● ●●● ●● ●● ●● ●● ● ●●●●● ●● ●● ●● ●●●● ●● ●● ●● ●●●● ●●● ●●● ● ●●● ●● ●●● ● ●● ●●●●●●● ●●● ● ●● ●● ●●●● ●●● ●● ● ●● ●● ●● ●●●● ●●●● ●● ●● ●●●● ●● ●● ●●●● ● ●● ●●● ●● ● ●● ●● ● ●● ● ●●●●●● ●● ●● ●●● ● ●● ●● ●● ●●● ●●●● ● ●●● ● ●● ●● ●●● ●● ●● ●●● ● ●●● ● ●● ●● ●●●● ● ●●●● ●● ●●● ●● ●●● ●●● ●● ●●● ●●● ● ● ●●● ●● ●●● ●●●● ●● ●● ●● ●● ● ●● ●● ●● ● ●● ●●● ●●● ●● ●● ●●● ●● ●● ● ●●● ●●●● ● ●●● ● ● ●●● ●● ● ●● ●●● ●● ●●●●● ●●● ● ● ●●●● ●● ●●● ●● ●●●● ●● ●●● ● ●● ●●● ●●●●● ●● ●● ●●● ●●● ●●● ●●●● ●●●● ●●● ●●● ●●●●● ●●● ● ●● ●●● ●● ●●● ●●●● ●●●● ●●●● ●●●● ●● ●● ● ●●●●● ●●●●● ●● ● ● ● ●● ●● ●●● ● ●● ●●● ●●● ●●● ●●● ●● ●● ●●● ●● ●● ●● ● ●●●● ● ●●● ●● ●● ●●● ●●●● ●● ●● ● ●● ●●● ● ● ● ● ●●●● ● ● ●●● ● ●● ●● ●●● ● ●● ● ●● ●●● ●●●● ●● ● ●● ●●● ● ●●● ● ●●●● ●● ●● ● ●● ● ●● ●● ●● ●●● ●● ● ● ●●● ●●● ● ●●● ●● ● ●●●● ● ●● ● ●●●●●●● ●● ●● ●● ●● ● ●● ● ●●●● ●●● ●●●● ● ●● ●● ●●● ●● ●●● ● ● ● ●●●● ●●●●●● ● ● ●● ●● ●● ● ● ●● ●●● ●●● ●● ●●●● ● ●● ● ●●● ●● ●● ● ● ●● ● ● ● ●● ●● ●●● ●● ●● ● ●●● ●● ●● ● ● ●●●●● ● ●●●● ●● ●●● ●●●● ●● ● ●●● ●● ● ●●●●●●●● ●●● ●●● ●● ● ●●● ●●●● ● ● ● ●●●● ● ●● ●● ●● ●●●● ● ●● ●● ●●● ●●● ●● ● ●●● ●●● ● ● ● ●●● ● ●●● ●● ● ●●● ●●●● ● ● ●●● ● ● ●● ● ● ●● ●● ●●● ● ●● ● ●●● ●●● ●●● ●●● ●●● ●●● ●● ●● ●● ●●● ●●● ●●● ●●●●●● ● ●● ●●● ● ●● ●● ●●● ●●● ● ●●●● ●● ●● ●● ● ●● ●● ●● ●●●●● ●● ●●●● ●●● ●● ●● ●●● ● ● ● ●●●● ●● ●●●● ● ●● ● ●●●●● ●●● ●● ●● ●●● ● ● ●●●● ●● ●●●● ●●●● ●● ● ●● ● ●●●● ●●● ● ● ●● ●●● ●● ●●●● ●● ● ●●● ●●● ●● ● ●● ●●● ●● ●● ●●● ●●●● ●● ●● ● ● ●● ● ● ●● ● ●●● ● ●● ●●●● ● ●●●● ●● ●● ●● ●●● ● ●●●● ●●● ●● ●● ●●●● ●● ●●● ●● ● ●● ●●● ●● ●● ● ●● ● ●●● ●●● ● ●● ● ●●● ●● ●● ● ●●● ●● ●● ●●●● ● ●●●● ● ●●●●●● ● ● ●●● ●● ●● ●●● ●●●●● ● ●●● ● ●●● ●● ● ●● ● ● ●● ● ●●● ● ● ●●● ●●● ● ●●●● ●● ● ●● ●● ●●● ● ●● ●● ●● ●● ●●● ● ●● ● ●● ● ●●● ●● ● ●● ● ●●● ●● ●●●●● ● ●● ● ●● ●●● ● ● ● ● ●●● ● ●●●● ●● ●● ● ●● ●●●● ●● ●● ● ● ● ●● ●● ●● ● ●●●● ●●● ●● ●●● ●●●● ●● ●● ●● ●●● ●●●●● ●● ● ●● ●● ●● ●●●● ●● ●●●● ●● ●● ● ● ●● ●● ●● ●● ●● ● ●●● ●●● ●● ● ●● ●● ●● ●● ●● ●● ●● ●● ●●●●● ●●● ●●● ●● ●● ●● ●● ●●● ● ●●● ● ●● ●● ●●● ●●● ●● ●●●●● ●● ●●● ●● ●● ●●● ●● ●● ●● ●● ● ●● ●● ●●●●● ●● ●● ●● ●●● ● ● ●● ●● ●●● ● ●●● ● ● ●●●●●● ●●●● ●●● ●● ●● ●● ●●● ● ● ● ●● ●●●● ● ●●●●● ●● ●● ●● ●● ●● ●●●● ● ●● ● ●●●● ●● ●●● ● ●●● ●● ●●●● ● ●● ●●● ● ●● ●●● ●● ● ●●●●● ●● ●● ●● ● ●● ●●● ●● ●● ●● ●●● ●●●●●● ●● ●●● ●●● ●●●●● ●● ● ●● ●●● ●● ● ●● ● ● ●●●●● ●● ● ●●● ● ●●● ●●●● ●● ●●● ●● ● ● ●●● ●● ●● ● ●●● ●●● ● ● ●● ●● ●● ●●● ●●● ●● ●●● ● ●●●● ●● ●●●●●●● ●● ● ●●● ●●● ●● ●● ●● ●● ●● ●● ● ●●● ● ●● ●●● ● ●● ●● ●● ●●● ●● ●● ●●●● ●● ●● ● ●●● ●● ●● ● ●●● ● ●● ● ●●● ●● ● ●●● ●● ●● ● ●● ●● ●●●●●● ● ●●● ●● ●● ● ●●● ●● ●● ●● ●●● ● ● ●● ●●● ●● ● ●● ●●●● ●●● ●● ●● ●● ●● ●●● ●● ●● ●●●● ● ●● ●● ●●● ●● ●● ●●● ● ●●●● ● ●●●●● ●● ● ● ● ●● ●●● ●● ●● ●●● ●● ● ●●●●● ● ●● ●●●● ●●●● ● ●●● ● ● ●● ●● ●● ●● ●●● ●●●● ●● ●●●●●● ●● ●● ●●●● ● ●● ● ●●●● ● ●●● ● ●● ● ●● ●● ● ●●● ●●●● ●● ●● ●● ●●●● ● ●●● ●● ●●● ● ●● ●● ● ● ● ●●●● ● ●● ●●● ●● ●● ●●●● ●●● ● ●● ● ●●● ● ●●●● ●●● ●● ● ●● ●●●● ●●● ●● ● ● ●● ●●● ●● ● ●● ●●● ●● ●● ● ● ●● ●● ● ●● ● ●●● ●● ● ● ●●● ●● ●● ●● ●● ●● ●●● ●●● ●● ●●● ● ●● ●●● ● ●● ●●●● ● ●● ●●●● ●●● ●●● ●●● ● ●●● ●●● ●● ● ● ●● ● ●●●●● ●● ●●●●● ●●● ● ● ●●●●● ●● ● ●●●●●●●● ●● ● ●●● ● ●● ●●● ● ●● ● ●● ●● ●● ●●●● ●● ●●● ●● ●●● ●●● ●●●● ● ●●● ●● ● ●●● ● ●● ●● ● ●●●● ● ●● ●●●● ●●● ● ● ●●● ●● ●● ● ● ●● ● ● ●●● ● ●●●● ● ●● ●●●●● ●●●●● ●● ●●● ●● ●● ●● ●● ● ●●● ●●● ● ●●● ●● ●● ●● ●●●●●●● ●● ●●● ● ●●● ● ●●● ●● ●●●● ● ●●● ●●● ● ●● ● ●●● ● ●● ●●● ●● ● ●● ●● ●●● ●● ●● ●●● ●● ●●●●●● ●● ●●● ●●● ●● ●● ●● ●● ●●●● ●●● ●● ●● ●●●● ●● ●●● ● ●●● ● ●● ● ●● ●● ●● ●● ●● ●●● ● ● ●● ● ● ●● ●●● ●● ●●●● ●●● ●● ●● ●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●●●

●●

●●

●●●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●●

●●

●●

●●

●●

●●●

●●

●●

●●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●●

●●●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●●

●●

●●

●●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●●

●●

●●●

●●

●●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●●

●●

●●

●●

●●●

●●

●●

●●

●●●

●●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●●

●●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●

●●●

●●

●●

●●

●●

●●

●CHC465T  (HCC)  

CHC464T  (HCA)  

-­‐>  There  is  clear  evidence  of  mul-ple  clones  in  the  HCA.  The  HCC  is  derived  from  subclone  1,  represen-ng  around  18%  of  tumor  cells  in  the  HCA  sample:  

HCA-­‐specific  variants  

HCC-­‐specific  variants  

Subclone  1  -­‐>  clonal  muta-ons  

Histogram of tmp$Tumor_Varprop

tmp$Tumor_Varprop

Frequency

0.0 0.1 0.2 0.3 0.4 0.5 0.6

0200

400

600

800

Histogram of tmp$Tumor_Varprop

tmp$Tumor_Varprop

Frequency

0.0 0.1 0.2 0.3 0.4 0.5 0.6

0500

1000

1500

2000

2500

3000

Variant  allele  frac-on  

Variant  allele  frac-on  

Freq

uency  

Freq

uency  

clonal  

subclone  1  (18%)  subclone  2  (35%)  

clonal  

subclonal  

Page 25: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

Ordonner  les  duplica-ons  chromosomiques  à  l'aide  des  muta-ons  6p  

X  

1q  

14  13  8   16/17  

CHC909T  

5  10  

0.0 0.2 0.4 0.6 0.8 1.0

−2−1

01

23

variant proportion

log

ratio

T/N

cov

erag

e

6p   6p  

X  

13/14  

8/16/17  

1q   1q  

Normal  copy-­‐number  

5  10  

5  10  

Variant  allele  frac-on  

0.0 0.2 0.4 0.6 0.8 1.0

−10

12

3

variant proportion

log

ratio

T/N

cov

erag

e

Late  

Early  

Variant  allele  frac-on  

Page 26: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

0.0 0.2 0.4 0.6 0.8 1.0

−10

12

3

variant proportion

log

ratio

T/N

cov

erag

e

0.0 0.2 0.4 0.6 0.8 1.0

−10

12

3

variant proportion

log

ratio

T/N

cov

erag

e

Chr  10  (late)  Chr  5  (early)  

!  The   ra-o   of   duplicated/non-­‐duplicated   muta-ons   depends   on   the   earliness   of   each  duplica-on  

!  ...  and  can  be  used  to  infer  the  molecular  -me  of  each  duplica-on:  

0   100  Point  muta-on  -me  

Muta-ons/chromosome  copy  (1309-­‐16)/3  16  

1309  16   Duplicated/non-­‐duplicated  muta-ons  

Time  =  16/(16+(1309-­‐16)/3)  =  4%  

4%  

Chr  5  duplica-on  

Page 27: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

0 20 40 60 80 100

+1+5 +6 +10

+17

+20 +Xloh

13loh

14loh

21

Point mutation time (%)

0 20 40 60 80 100

+1 +3+5+8 +11

+12

+15

+19 +X

Point mutation time (%)

0 20 40 60 80 100

+8 +X

Point mutation time (%)

0 20 40 60 80 100

+1+2 +8+15

Point mutation time (%)

!  Timing  chromosome  duplica-ons  in  hepatocellular  carcinomas:  

+1 +10

+11

+12

+13

+15

+17

+19 +2 +20

+21 +3 +4 +5 +6 +7 +8 +X

0

20

40

60

80

100

Recurrent CNAs

Poin

t mut

atio

n tim

e

●●●

●●

●●

●●

●●●

●●●

●●

●●

●●

!  Molecular  -me  distribu-on  for  recurrent  chromosome  duplica-ons:  

Page 28: Signatures+mutaonnelles +et évolu-on+ clonaledes tumeurs++ · aca acc acg act cca ccc ccg cct gca gcc gcg gct tca tcc tcg tct aca acc acg act cca ccc ccg cct gca gcc gcg gct tca

!  Comprendre   l'évolu-on   clonale   des   tumeurs   est   capital   pour   l'u-lisa-on   des  marqueurs  géné-ques  en  clinique  

!  Diverses   approches   permeyent   de   reconstruire   l'évolu-on   clonale   et   l'ordre  d'appari-on  des  altéra-ons  géné-ques  chez  un  pa-ent  

!  Les  données  de  séquençage  génome  complet  nous  offrent  une  vision  dynamique  du  développement  tumoral.  

ÉVOLUTION  CLONALE  DES  TUMEURS  

!  Les  échan-llons  tumoraux  portent  les  traces  des  processus  mutagènes  auxquels  ils  ont  été  soumis  

SIGNATURES  MUTATIONNELLES  

!  Les   signatures  muta-onnelles   sont  un   formidable  ou-l  pour   comprendre   les   liens  entre  exposi-ons  environnementales,  prédisposi-ons  géné-ques  et  cancer  

!  31  signatures  muta-onnelles  ont  été   iden-fiées  à  ce   jour,  dont  une  bonne  moi-é  restent  inexpliquées.  

Conclusions